-
Product Insights
Acute Ischemic Stroke – Drugs In Development, 2023
Global Markets Direct’s, ‘Acute Ischemic Stroke - Drugs In Development, 2023’, provides an overview of the Acute Ischemic Stroke pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Ischemic Stroke, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Sepsis – Drugs In Development, 2023
Global Markets Direct’s, ‘Sepsis - Drugs In Development, 2023’, provides an overview of the Sepsis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sepsis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Ischemic Stroke – Drugs In Development, 2023
Global Markets Direct’s, ‘Ischemic Stroke - Drugs In Development, 2023’, provides an overview of the Ischemic Stroke pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ischemic Stroke, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MRNA-1011.2 in Seasonal Influenza
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MRNA-1011.2 in Seasonal Influenza report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.MRNA-1011.2 in Seasonal InfluenzaDrug Details:mRNA-1011.2 is under development for the prevention of seasonal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 3K3A-APC in Wounds
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 3K3A-APC in Wounds report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. 3K3A-APC in Wounds Drug Details: 3K3A-APC is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 3K3A-APC in Amyotrophic Lateral Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 3K3A-APC in Amyotrophic Lateral Sclerosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.3K3A-APC in Amyotrophic Lateral Sclerosis Drug Details:3K3A-APC is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ruxolitinib Phosphate in Hypereosinophilic Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ruxolitinib Phosphate in Hypereosinophilic Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ruxolitinib Phosphate in Hypereosinophilic Syndrome Drug Details: Ruxolitinib (INCB18424, Jakafi, Jakavi)...
-
Product Insights
ZZ Power – Zhoushan Ultra Supercritical Coal-Fired Power Plant Expansion Phase III 1320 MW – Zhejiang
Equip yourself with the essential tools needed to make informed and profitable decisions with our ZZ Power - Zhoushan Ultra Supercritical Coal-Fired Power Plant Expansion Phase III 1320 MW - Zhejiang report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report?...